Overview

Organoids Predict Therapeutic Response in Patients With Multi-line Drug-resistant Non-small Cell Lung Cancer

Status:
Not yet recruiting
Trial end date:
2026-05-31
Target enrollment:
Participant gender:
Summary
This is a single-center, single-arm, open and exploratory clinical study. The purpose of this study was to evaluate the consistency and accuracy of the organogenic (PDO) model for patients with lung cancer, to predict the clinical efficacy of anticancer drugs, and to speculate and select personalized treatment regiments for patients with non-small cell lung cancer who are resistant to multi-line standard therapies.
Phase:
Phase 2
Details
Lead Sponsor:
Affiliated Hospital of Jiangnan University